Preview

Онкоурология

Расширенный поиск

РСА3 – ИСТИННЫЙ ОНКОМАРКЕР РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ (ОБЗОР ЛИТЕРАТУРЫ)

https://doi.org/10.17650/1726-9776-2014-10-2-70-77

Полный текст:

Аннотация

Рутинное измерение уровня простатспецифического антигена (ПСА) привело к увеличению количества выполняемых биопсий предстательной железы (ПЖ). Снижение порога возрастных норм ПСА привело, в свою очередь, к увеличению числа «ненужных» биопсий ПЖ (к гипердиагностике клинически незначимого рака ПЖ (РПЖ)). В настоящее время только у 35 % пациентов с уровнем общего ПСА 4–10 нг/мл удается при биопсии выявлять РПЖ, а у 20–25 % мужчин имеет место «ПСА-негативный» РПЖ. Очевидно, что ПСА как самостоятельный маркер исчерпал свои диагностические возможности. Описанные в новейшей литературе новые онкомаркеры РПЖ, несомненно, заслуживают пристального внимания и изучения. Наиболее перспективным биомаркером из всего многообразия является РСА3.

РСА3 является лучшим предиктором РПЖ при выполнении первичной либо повторной биопсии ПЖ по сравнению с общим ПСА или другими его производными. Некоторые публикации показали возможность использования индекса РСА3 при планировании пер-вичной либо повторной биопсии ПЖ, с построением номограмм рисков, в комплексе с другими индивидуальными показателями обследования пациента, в том числе с другими новейшими биомаркерами РПЖ. Применение РСА3 в повседневной практике может способствовать увеличению специфичности диагностики РПЖ и уменьшить количество «ненужных» биопсий ПЖ.

 

Об авторах

А. В. Сидоренков
Кафедра урологии МГМСУ им. А.И. Евдокимова Минздрава России
Россия


Д. Ю. Пушкарь
Кафедра урологии МГМСУ им. А.И. Евдокимова Минздрава России
Россия


Список литературы

1. Состояние онкологической помощи на-селению России в 2011 г. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой М., 2012. С. 17–29.

2. Babaian R.J., Mettlin C, Kane R. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992;69:1195–200.

3. Cooner W.H., Mosley B.R., Ruterford CL. et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143(6):1146–52.

4. Лоран О.Б., Пушкарь Д.Ю., Степанов В.П., Крохотина Л.В. Дифференциальная диаг-ностика опухолей предстательной железы с помощью определения уровня простат-специфического антигена сыворотки кро-ви. М., 2000.

5. Лоран О.Б., Пушкарь Д.Ю., Франк Г.А. Простатспецифический антиген и морфо-логическая характеристика рака предста-тельной железы: Руководство для врачей. М.: МЕД-пресс, 1999.

6. Bangma C.N., Kranse R., Blijenberg B.G., Schroder F.H. The free-to-total serum prostate specific antigen ratio for staging prostatic carcinoma. J Urol 1997;157(Suppl 2): 544–7.

7. Catalona W.J. Clinical utility of measurements of free and total prostate-specific antigen (PSA). Prostate 1996; Suppl 7:64–9.

8. Seamen E., Whang M. Prostate-specific antigen density (PSAD): pole in patient evaluation and management. Urol Clin North Am 1993;20:653.

9. Cuvillier O., Malavaud B. Biomarkers of aggressiveness in prostate cancer. Prostate cancer – diagnostic and therapeutic advances. November – 2011; р. 3–20.

10. Bussemakers M.J., van Bokhoven A., Verhaegh G.W. et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999;59(23):5975–9.

11. Day J.R., Jost M., Reynolds M.A. et al. PCA3: from basic molecular science to the clinical lab. Cancer Lett 2011;301:1–6.

12. Bourdoumis A., Papatsoris A.G., Chrisofos M. et al. The novel prostate cancer antigen 3 (PCA3) biomarker. Int Braz J Urol 2010;36(6):665–8.

13. de Kok J.B., Verhaegh G.W., Roelofs R.W. et al. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002;62(9):2695–8.

14. Fradet Y., Saad F., Aprikian A. et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64(2):311–5.

15. Tinzl M., Marberger M., Horvath S., Chypre C. DD3 PCA3 RNA analysis in urine – a new perspective for detecting prostate cancer. Eur Urol 2004;46(2):182–6.

16. Deras I.L., Aubin S.M., Blase A. et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179(4):1587–92.

17. Groskopf J., Aubin S.M., Deras I.L. et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006;52(6):1089–95.

18. Haese A., de la Taille A., van Poppel H. et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54(5):1081–8.

19. Leonard S. Marks and David G. Bostwick Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Rev Urol 2008;10(3):175–81.

20. Van Gils M.P., Hessels D., van Hooij O. et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007;13(3):939–43.

21. Hessels D., Schalken J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6(5):255–61.

22. de la Taille A., Irani J., Graefen M. et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011;185(6):2119–25.

23. Hessels D., Klein Gunnewiek J.M., Oort I. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44(1):8–15.

24. Ankerst D.P., Groskopf J., Day J.R. et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol 2008;180:1303–8.

25. Chun F.K., de la Taille A., van Poppel H. et al. Prostate cancer gene 3 (PCA3): Development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659–68.

26. van Gils M.P., Hessels D., Hulsbergen-van de Kaa C.A. et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008;68:1215–22

27. Nakanishi H., Groskopf J., Fritsche H.A. et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008;179:1804–9.

28. van Poppel H., Haese A., Graefen M. et al. The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012;109(3):360–6.

29. Auprich M., Chun F.K., Ward J.F. et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011;59: 96–105.

30. Hessels D., van Gils M.P., van Hooij O. et al. Predicitve value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010;70:10–6.

31. Ploussard G., Durand X., Xylinas E. et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011;59:422–9.

32. Pepe P., Fraggetta F., Galia A., Aragona F. Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy? Urol Int 2012;89(2):143–7.

33. Whitman E.J., Groskopf J., Ali A. et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975–8.

34. Тosoian J.J., Loeb S., Kettermann A. et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010;183:534–8.

35. Crawford E.D., Rove K.O., Trabulsi E.J. et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: A prospective study of 1,962 cases. J Urol 2012;188:1726–31.

36. Ochiai A., Okihara K., Kamoi K. et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 2011;18:200–5. 37. Salagierski M., Mulders P., Schalken J.A. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 2013;33:553–7.

37. Auprich M., Haese A., Walz J. et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010;8:727–32.

38. Wu A.K., Reese A.C., Cooperberg M.R. et al. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis 2012;15:100–5.

39. Hansen J., Auprich M., Ahyai S.A. et al. Initial prostate biopsy: Development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol 2013;63:201–9.

40. Ruffion A., Devonec M., Champetier D. et al. PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci 2013;14(9):17767–80.

41. Galasso F., Giannella R., Bruni P. еt al. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study. Arch Ital Urol Androl 2010;82(1):5–9.

42. Gittelman M.C., Hertzman B., Bailen J. еt al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013;190(1):64–9.

43. Pepe P., Aragona F. PCA3 score vs PSA free/total accuracy in prostate cancer diagnosis at repeat saturation biopsy. Anticancer Res 2011;31(12):4445–9.

44. Кишкун А.А. Клиническая лаборатор-ная диагностика: учебное пособие. М., 2010. С. 32–33.

45. De Koning H.J., Essink-Bot M.L., Schroder F.H. Screening for prostate cancer. In: Prostate cancer. Clinical and scientific aspects – bridging the gap. P.D. Abel, E.-N. Lafani (eds.). London, United Kingdom: Imperial College Press, 2003. P. 683–708.

46. Roddam A.W., Hamdy F.C., Allen N.E., Price C.P. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. BJU Int 2007;100:514–7.

47. Leitenberger A., Altwein J.E. Efficacy and discriminative ability of prostate-specific antigen as a tumor marker. Eur Urol 1990;17(1):12–6.

48. Mettlin C., Lee F., Drago J., Murphy G.P. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67(12):2949–58.

49. Teillac P., Bron J., Tobolski F. et al. Detection of cancer of the prostate. A study of 600 cases. Ann Urol (Paris) 1990;24(1):37–41.

50. Schilling D., Hennenlotter J., Munz M. et al. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Urol Int 2010;85(2):159–65.

51. Hammerer P., Huland H. Systemic sextant biopsies in 651 patients referred for prostate evaluation. J Urol 1994;151:99–102.

52. Hodge K.K., McNeal J.E., Terris M.K. et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71–5.

53. Livene M.A., Ittman M., Melamed J. et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate on predicting Gleason score of prostate cancer. J Urol 1998;159:471–6.

54. Svetec D., McCabe K., Peretsman S. et al. Prostate rebiopsy is a poor surrogate of treat-ment efficacy in localized prostate cancer. J Urol 1998;159:1606–8.

55. Говоров А.В. Оптимизация трансрек-тальной биопсии простаты в диагностике рака предстательной железы. Автореф. дис. ... канд. мед. наук. М., 2002.

56. Guichard G., Larrй S., Gallina A. et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007;52:430–5.

57. Applewhite J.C., Matlaga B.R., McCullough D.L. Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol 2002;168:500–3.

58. Djavan B., Ravery V., Zlotta A. et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679–83.

59. Marks L.S., Fradet Y., Deras I.L. et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532–5.

60. Aubin S.M., Reid J., Sarno M.J. et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010;184:1947–52.62. Adam A., Engelbrecht M.J., Bornman M.S. et al. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Int 2011;108:1728–33.

61. Clarke R.A., Zhao Z., Guo A.Y. et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009;4(3):4995.

62. Laxman B., Morris D.S., Yu J. et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008;68:645–9.

63. Ouyang B., Bracken B., Burke B. et al. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009;181:2508–13.

64. Stephan C., Jung K., Semjonow A. et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59(1):280–8.

65. Robert G., Jannink S., Smit F. et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 2013;73(2):113–20.


Для цитирования:


Сидоренков А.В., Пушкарь Д.Ю. РСА3 – ИСТИННЫЙ ОНКОМАРКЕР РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ (ОБЗОР ЛИТЕРАТУРЫ). Онкоурология. 2014;10(2):70-77. https://doi.org/10.17650/1726-9776-2014-10-2-70-77

For citation:


Sidorenkov A.V., Pushkar D.Y. PCA3 IS A TRUE ONCOMARKER OF PROSTATE CANCER: A REVIEW OF LITERATURE. Cancer Urology. 2014;10(2):70-77. (In Russ.) https://doi.org/10.17650/1726-9776-2014-10-2-70-77

Просмотров: 807


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)